Please ensure Javascript is enabled for purposes of website accessibility

FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality

By Brian Orelli, PhD - Feb 21, 2020 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A clinical trial suggests the COPD drug reduces the risk of death compared to GSK's older treatment, but the agency has concerns about the study's design.

The Food and Drug Administration is asking one of its panels of outside experts to help it make a decision about GlaxoSmithKline's (GSK 0.84%) request to add data to the label of Trelegy Ellipta, its chronic obstructive pulmonary disease (COPD) drug. The pulmonary-allergy drugs advisory committee will meet on April 21 to discuss whether the claim that Trelegy Ellipta reduces mortality should be added to the drug's label. That would allow the company to use the information in its marketing materials.

Results from the Informing the Pathway of COPD Treatment (IMPACT) clinical trial showed that Trelegy Ellipta reduced the risk of on-treatment all-cause mortality by 42.1% compared to Anoro, which contains two of the three medications in Trelegy Ellipta.

But the FDA seems to be concerned that 70% of patients treated with Anoro in the study were taking inhaled corticosteroids beforehand, and had to go off of them during the trial, which might have affected the results. An editorial in the New England Journal of Medicine chastised the company for the trial's "design peculiarity."

Senior man using an inhaler

Image source: Getty Images.

Investors in Innoviva (INVA 1.87%), which developed the drug back when the company was called Theravance, and licensed it to GlaxoSmithKline, should also be watching the advisory committee meeting since Innoviva gets royalties on sales of the drug.

Investors will get a first look at what the FDA thinks of the claim on April 18 when the agency posts the documents it will send to the committee.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$36.03 (0.84%) $0.30
Innoviva, Inc. Stock Quote
Innoviva, Inc.
INVA
$14.74 (1.87%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.